Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine

Sarah A. Kopecky-Bromberg, Kathryn A. Fraser, Natalie Pica, Elena Carnero, Thomas M. Moran, Richard W. Franck, Moriya Tsuji, Peter Palese

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Abstract

There is a substantial need to develop better influenza virus vaccines that can protect populations that are not adequately protected by the currently licensed vaccines. While live attenuated influenza virus vaccines induce superior immune responses compared to inactivated vaccines, the manufacturing process of both types of influenza virus vaccines is time consuming and may not be adequate during a pandemic. Adjuvants would be particularly useful if they could enhance the immune response to live attenuated influenza virus vaccines so that the amount of vaccine needed for a protective dose could be reduced. The glycolipid, alpha-galactosylceramide (alpha-GalCer), has recently been shown to have adjuvant activity for both inactivated and replicating recombinant vaccines. The goal of these experiments was to determine whether a derivative of alpha-GalCer, alpha-C-galactosylceramide (alpha-C-GalCer) can enhance the immune response elicited by a live attenuated influenza virus vaccine containing an NS1 protein truncation and reduce the amount of vaccine required to provide protection after challenge. Our results indicated that the adjuvant reduced both morbidity and mortality in BALB/c mice after challenge with wild type influenza virus. The adjuvant also increased the amount of influenza virus specific total IgG, IgG1, and IgG2a antibodies as well as IFN-γ secreting CD8+ T cells. By using knockout mice that are not able to generate NKT cells, we were able to demonstrate that the mechanism of adjuvant activity is dependent on NKT cells. Thus, our data indicate that stimulators of NKT cells represent a new avenue of adjuvants to pursue for live attenuated virus vaccines.

Original languageEnglish (US)
Pages (from-to)3766-3774
Number of pages9
JournalVaccine
Volume27
Issue number28
DOIs
StatePublished - Jun 8 2009

Bibliographical note

Funding Information:
This work was partially supported by the Bill and Melinda Gates Foundation (grant 38648; David Ho, PI), NIH grant (1 U01 AI070469), the NIH training grant T32 A1007645 (S.A.K-B and K.F.), the Northeast Biodefense Center (U54AI057158), and by NIH grant RO1 AI 41111 (T.M). We thank Lily Ngai for excellent technical assistance. We especially thank Dr. Michael Brenner and Dr. Elizabeth Leadbetter for access to the CD1d−/− mice.

Keywords

  • Adjuvant
  • Alpha-C-galactosylceramide
  • Influenza virus
  • Vaccine

Fingerprint

Dive into the research topics of 'Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine'. Together they form a unique fingerprint.

Cite this